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ABSTRACT  1 
Fatiguing exercise is the basis of exercise training and a cornerstone of management of type 2 2 
diabetes mellitus (T2D), however, little is known about the fatigability of limb muscles and the 3 
involved mechanisms in people with T2D.  The purpose was to compare fatigability of knee 4 
extensor muscles between people with T2D and controls without diabetes and determine the 5 
neural and muscular mechanisms for a dynamic fatiguing task. Seventeen people with T2D (10 6 
men, 7 women: 59.6±9.0 years) and 21 age-, BMI- and physical activity-matched controls (11 7 
men, 10 women: 59.5±9.6 years) performed 120 high-velocity concentric contractions (1 8 
contraction/3 s) with a load equivalent to 20% maximal voluntary isometric contraction (MVIC) 9 
torque with the knee extensors. Transcranial magnetic stimulation (TMS) and electrical 10 
stimulation of the quadriceps were used to assess voluntary activation and contractile properties. 11 
People with T2D had larger reductions than controls in power during the fatiguing task 12 
(42.8±24.2% vs. 26.4±15.0%, P<0.001) and MVIC torque after the fatiguing task (37.6±18.2% 13 
vs. 26.4±12.1%, P=0.04). People with T2D had greater reductions than controls in the 14 
electrically-evoked twitch amplitude after the fatiguing task (44.0±20.4% vs. 35.4±12.1%, 15 
respectively, P=0.01).  However, the decrease in voluntary activation was similar between 16 
groups when assessed with electrical stimulation (12.1±2.6% vs. 12.4±4.4% decrease, P=0.84) 17 
and TMS (P=0.995). A greater decline in MVIC torque was associated with larger reductions of 18 
twitch amplitude (r
2
=0.364, P=0.002). Although neural mechanisms contributed to fatigability, 19 
contractile mechanisms were responsible for the greater knee extensor fatigability in men and 20 
women with T2D compared with healthy controls. 21 
  22 
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New & Noteworthy: Transcranial magnetic stimulation and percutaneous muscle stimulation 23 
were used to determine the contributions of neural and contractile mechanisms of fatigability of 24 
the knee extensor muscles after a dynamic fatiguing task in men and women with type 2 diabetes 25 
(T2D) and healthy, age-, BMI- and physical activity-matched controls. Although neural and 26 
contractile mechanisms contributed to greater fatigability of people with T2D, fatigability was 27 
primarily associated with impaired contractile mechanisms and glycemic control.   28 
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Key Words (5): muscle fatigue, diabetes mellitus, skeletal muscle, sex differences, knee extensors 29 
Abbreviations:  30 
ANOVA Analysis of Variance 31 
BMI  Body Mass Index 32 
DEXA  Dual X-ray Absorptiometry  33 
EMG  Electromyography 34 
FPG  Fasting Plasma Glucose Concentration 35 
FPI  Fasting Plasma Insulin Concentration 36 
HbA1c  Glycated Hemoglobin 37 
HOMA-IR Homeostatic Model Assessment of Insulin Resistance 38 
MEP  Motor Evoked Potential 39 
min  Minute 40 
Mmax  Maximal Compound Muscle Action Potential 41 
MVCC Maximal Voluntary Concentric Contractions 42 
MVIC  Maximal Voluntary Isometric Contractions 43 
SIT  Superimposed Twitch 44 
T2D  Type 2 Diabetes Mellitus 45 
TMS  Transcranial Magnetic Stimulation   46 
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INTRODUCTION 47 
Type 2 diabetes mellitus (T2D) has become a global pandemic and is estimated to 48 
currently affect 8% of the world’s population (34). Physical activity is a cornerstone of T2D 49 
management and along with diet is the first intervention used to treat T2D (43). Incidence of 50 
T2D can be reduced by 58% with lifestyle interventions (diet, weight loss and exercise), and 51 
these lifestyle interventions were almost twice as effective as pharmacological treatment 52 
(metformin), which reduced the incidence of diabetes by 31% (30). Fatiguing contractions of 53 
limb muscles are the foundation of exercise training and the neuromuscular adaptations that 54 
accompany regular exercise (31). However, there is minimal understanding of the mechanisms 55 
that limit a single bout of fatiguing exercise in people with T2D.  56 
Fatigability of limb muscles is a reversible, short-term and activity-induced reduction in 57 
muscle strength or power (17, 23), and can limit performance of daily tasks that require repeated 58 
or sustained contractions (12, 42). Mechanisms that contribute to limb fatigability in healthy 59 
adults include deficits in neural drive to the muscle, impairments in neuromuscular propagation, 60 
reduced force capacity of skeletal muscle fibers, and impaired blood flow to the muscle (11, 17, 61 
23). Few studies have examined the mechanisms of fatigability among people with diabetes. 62 
Several studies have shown that for isometric contractions with lower limb muscles (ankle 63 
dorsiflexor and knee extensor muscles), people with type 1 diabetes and diabetic polyneuropathy 64 
and people with T2D, were more fatigable than controls (3, 6, 8). The mechanisms contributing 65 
to greater fatigability in the people with type 1 diabetes who had diabetic polyneuropathy 66 
included disruption of neuromuscular transmission indicated by a concomitant decrease in the 67 
maximal compound muscle action potential (3) and slowed motor unit conduction velocities and 68 
discharge frequencies (6). The mechanisms for the greater fatigability in the lower limb muscles 69 
of people with T2D are not known.  70 
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Decrements in power during repeated dynamic fatiguing contractions are probably of 71 
greater functional significance than decrements in torque during isometric tasks in people with 72 
T2D.  First, at baseline (without fatigue) the difference (reduction) in muscle power for people 73 
with T2D compared with controls is greater than for maximal isometric torque (2, 22). Second, 74 
low power and maximal velocity of limb muscles at baseline were the primary variables 75 
associated with impaired balance and gait in people with T2D (36). Whether people with T2D 76 
are more fatigable during dynamic contractions, which can further exacerbate power differences 77 
between controls and people with T2D, is relatively unexplored.  One study demonstrated that 78 
after 20 moderate-velocity (120 deg·s
-1
) isokinetic contractions performed separately with four 79 
lower limb muscle groups, people with T2D (with and without diabetic polyneuropathy) were 80 
more fatigable than age-matched controls for the knee flexor muscles, but not the ankle plantar 81 
flexor or dorsiflexor, or knee extensor muscles (28). Another study, showed that people with 82 
T2D tended to have greater reductions in knee extensor torque over 30 isokinetic contractions at 83 
180 deg·s
-1
 than healthy age-matched controls (both lean and weight-matched), although these 84 
differences in torque reductions did not reach statistical significance, possibly due to low subject 85 
numbers (n = 8) (18). There are no other known studies determining the fatigability during 86 
dynamic fatiguing tasks in people with T2D, and furthermore, the mechanisms are unknown. 87 
Lastly, despite potential differences in fatigability between men and women (24), studies of 88 
fatigability in people with T2D have been underpowered to determine whether there are sex-89 
related differences among people with T2D (e.g. (8, 18, 28, 37). 90 
The mechanisms for any potential increased fatigability of limb muscles in men and 91 
women with T2D may originate from both neural (supraspinal and spinal) and muscular sites. 92 
People with T2D may have impaired skeletal muscle energetics (i.e. increased inorganic 93 
phosphate and hydrogen ion within intracellular milieu) and reduced skeletal muscle blood flow 94 
during exercise compared with healthy controls (32, 39), potentially eliciting greater stimulation 95 
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of afferent feedback (Group III and IV afferents) to supraspinal and spinal centers during 96 
fatiguing exercise, further exacerbating any exercise-related reductions in neural drive to the 97 
muscle (23, 46). Furthermore, because people with T2D are at risk of neuropathy, neuromuscular 98 
transmission may contribute to differences in fatigability between people with and without T2D 99 
(2, 3).  In this current study, we used non-invasive stimulation at the motor cortex and muscle to 100 
determine the contribution of neural (supraspinal and spinal) and muscular mechanisms (50, 51) 101 
to any differences in fatigability between people with T2D and controls.  102 
The purpose of the study was to: 1) compare fatigability of both men and women with 103 
T2D (without clinically-evident neuropathy) with age-, BMI- and physical activity-matched 104 
controls in response to a high-velocity dynamic fatiguing task with the knee extensor muscles, 105 
and 2) determine the contribution of neural and muscular mechanisms. Our hypotheses were that: 106 
1) fatigability of the knee extensor muscles would be greater in people with T2D compared with 107 
healthy controls, and 2) both neural and contractile mechanisms would contribute to the greater 108 
fatigability in people with T2D compared with healthy control participants. Because the age of 109 
onset of T2D is inversely related to disease complication risk and mortality, we enrolled 110 
participants >50 years. Additionally, because there is limited understanding of sex differences in 111 
fatigability of people with T2D, a third aim was to determine whether there were sex-related 112 
differences in fatigability and mechanisms among people with T2D. Our hypothesis was that 113 
there would be no sex-related differences in fatigability, as we have observed in a young and 114 
older adult population previously (42).  115 
MATERIALS AND METHODS  116 
Seventeen people with T2D (10 men: age, 59.7 ± 9.5 years; HbA1c, 6.92 ± 1.19%; 7 117 
women: age, 59.6 ± 9.0 years; HbA1c, 7.20 ± 1.06%) and twenty-one healthy controls (11 men: 118 
age, 58.2 ± 10.3 years; HbA1c, 5.42 ± 0.25%; 10 women: age, 61.2 ± 8.8 years; HbA1c, 5.40 ± 119 
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0.21%) participated in the study. Prior to involvement in the study, each participant provided 120 
written informed consent and the protocol was approved by the Marquette University 121 
Institutional Review Board (HR-2402) for ethical approval in accordance with the Declaration of 122 
Helsinki for human experimentation. 123 
Aside from glycemic control, all participants were healthy. Type 2 diabetes was 124 
physician-diagnosed and confirmed at study enrolment via fasting glucose and HbA1c. Exclusion 125 
criteria included: unstable diabetes, prescribed insulin or insulin secretagogue, poor glycemic 126 
control (glycosylated hemoglobin (HbA1c) >10%), diabetic neuropathy (assessed via clinical 127 
diagnosis, monofilament and tuning fork sensation tests, and sensory questionnaires), peripheral 128 
edema, severe obesity (body mass index, BMI, >45 kg/m
2
), untreated hypothyroidism, epilepsy, 129 
medications that affect cortical excitability, possibility of pregnancy and any neurological, 130 
cardiovascular or musculoskeletal disease that precluded exercise testing. Any potential 131 
participants who presented with HbA1c >5.7% and <6.5% (and were not diagnosed with T2D) 132 
were classified as having pre-diabetes and not included in the study; thus, all controls had an 133 
HbA1c ≤5.6%.  134 
Participants completed three sessions of testing that included a screening session to 135 
determine eligibility for the study followed by two experimental sessions. The aim of the first 136 
experimental session was to familiarize participants with experimental procedures and complete 137 
a fasting blood draw and questionnaires. The aim of the second experimental session was to 138 
complete the fatiguing task. Each session was separated by 2-7 days.  139 
Screening Session 140 
 During the screening session, the following tests were performed: 1) lower limb sensation 141 
was assessed using a 10-gram monofilament and 128-Hz vibration sensation test, 2) autonomic 142 
nerve function was assessed using a heart rate variability test and blood pressure response to 143 
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upright posture, and 3) glycemic control was assessed using a point-of-care HbA1c instrument. 144 
Skeletal muscle mass of the dominant leg and whole-body fat mass were assessed utilizing 145 
DEXA and participants were assigned a triaxial accelerometer. Then, peak aerobic capacity was 146 
estimated from a submaximal graded bicycle ergometer exercise test. 147 
Diabetic neuropathy screening: Each participant was screened for the presence of diabetic 148 
polyneuropathy. To assess symptoms and signs of sensory neuropathy monofilament screening 149 
of the feet, vibration sensation testing (bilateral malleoli and heads of the 1
st
 metatarsals) and 150 
Achilles tendon reflex testing were performed. Participants were excluded if impaired sensation 151 
was observed i.e., if the monofilament could not be sensed on any site on the foot; if vibrations 152 
could be sensed by the examiner for more than 10 s longer than the participant; or if the tendon 153 
jerk was absent. Participants who were suspected of having diabetic polyneuropathy (sensory or 154 
autonomic) were excluded from the study.  155 
HbA1c: HbA1c was determined using blood from a fingerstick, analyzed using a point-of-care 156 
instrument assay (Siemens Healthcare Diagnostics, DCA 2000+). 157 
Anthropometry and DEXA: Body anthropometry included measurements of height, body mass 158 
and waist circumference. Skeletal muscle mass of the dominant leg and whole-body fat mass (% 159 
body weight), were assessed utilizing DEXA (Lunar Prodigy full-body scanner, Madison, WI, 160 
USA). The scanner was calibrated prior to each scan. The analyzed data was recorded offline 161 
(Encore 2008 software by GE Health care). In the case of participants with artificial joints (n = 162 
4), the artificial joint was excluded via encore software.  163 
Physical Activity Monitor: Accelerometry data were collected using the Actigraph GT3X 164 
(ActiGraph, Pensacola, FL, USA) that was worn on the hip by each participant for 4 days (2 165 
weekdays and 2 weekend days). Sixty-second epochs of data were collected and analyzed. Wear-166 
time authentication was performed on each participant’s dataset to determine whether data were 167 
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to be included in the analysis. Acceptable wear-time was set a priori and defined as ≥ 3 days of ≥ 168 
9 hours (540 minutes) per day. Step count was recorded (ActiLife Software v4) and analyzed.  169 
Submaximal, Graded Bicycle Test: Participants performed a submaximal graded exercise test (9) 170 
on a bicycle ergometer (VIAsprint 150P, CareFusion, San Diego, CA, USA) to determine 171 
estimated oxygen consumption and to screen for exercise-induced cardiac arrhythmia. 172 
Participants were required to maintain cadence of 60 revolutions per minute that was monitored 173 
via LED screen by the participant and a researcher, and the cycle load was manipulated to attain 174 
three submaximal loads that elicited incremental heart rate responses between 40% and 70% of 175 
heart rate reserve. The participant cycled at each submaximal load for four minutes to attain 176 
steady-state. During this test, a 12-lead electrocardiogram (CASE, General Electrics, Madison, 177 
WI, USA) was monitored to determine if arrhythmias were present. Participants were excluded if 178 
arrhythmia was detected, even if asymptomatic.  179 
Experimental Session One 180 
Participants fasted for at least 8 hours prior to experimental session one. Venous blood 181 
was obtained via venous draw, after which participants consumed a standardized breakfast (8 oz. 182 
fruit juice, one cereal bar, and one serving of fruit) prior to undertaking the remaining activities 183 
in the session. In conjunction with fasting, participants with T2D delayed administration of 184 
medications until after the venous draw.  185 
Participants completed a questionnaire to determine handedness/footedness (35) to assess 186 
which leg which would be used for testing. Participants first practiced submaximal muscle 187 
contractions, maximal voluntary isometric contractions (MVICs) and maximal voluntary 188 
concentric contractions (MVCCs) of the knee extensor muscles while seated in a Biodex System 189 
4 dynamometer (Biodex Medical, Shirley, NY). They were also habituated with electrical 190 
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stimulation of the femoral nerve, percutaneous electrical stimulation of the knee extensor 191 
muscles and transcranial magnetic stimulation (TMS) of the motor cortex.  192 
Blood Measures: Fasting blood glucose was determined using a point of care instrument (Alere 193 
Cholestech LDX System, Alere Inc. Waltham, MA, USA). Hemoglobin concentration was 194 
determined using a point of care instrument (StatSiteM Hemoglobin Photometer, Stanbio, 195 
Boerne, TX, USA) and hematocrit was determined manually (International Micro-capillary 196 
Reader, International Equipment Company, Boston, MA, USA) per standard instruction of each 197 
instrument. Plasma insulin and thyroid-stimulating hormone concentrations were quantitatively 198 
assayed in duplicate per manufacturer instructions using enzyme-linked immunoassay kits 199 
(Quantikine Human Insulin Immunoassay (R&D Systems, Minneapolis, MN) and Human TSH 200 
(CGA) ELISA Kit (Thermo Scientific Pierce (Waltham, MA), respectively).  201 
Questionnaires: All participants completed questionnaires to assess: clinical symptoms of fatigue 202 
using the Fatigue Impact Scale (13); sleep quality with the Pittsburgh Sleep Quality Index (10); 203 
and depression with the short form Geriatric Depression Scale (44). 204 
Experimental Session Two 205 
Participants consumed the same standardized breakfast as during the first experimental 206 
session; after which participants with T2D administered their diabetes medications. In this 207 
second experimental session, each participant performed baseline MVICs and MVCCs followed 208 
by a maximal-velocity fatiguing task and recovery contractions with the dominant knee extensor 209 
muscles. 210 
Measurement of Torque, Velocity and Power 211 
Participants performed isometric and isotonic contractions with the knee extensors 212 
muscles while seated in a dynamometer. Participants performed all contractions on their 213 
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dominant leg, unless there was any form of disease (e.g. osteoarthritis) or injury (e.g. knee 214 
reconstruction), in which case the non-dominant leg was tested (n = 2 controls, 2 people with 215 
T2D). Participants were seated with 90º of hip flexion. Padded straps mounted on the seat were 216 
securely tightened across the shoulders, the waist, and the non-dominant leg to minimize 217 
synergistic movements. The dominant leg was positioned such that the axis of rotation of the 218 
knee joint was aligned with the axis of rotation of the dynamometer. The internal goniometer of 219 
the Biodex dynamometer was calibrated using a level to measure 90º flexion of the knee joint. 220 
The analog signals corresponding to joint angle, torque, and velocity were digitized and recorded 221 
through a Power 1401 analog-to-digital (A-D) converter and Spike2 software (Cambridge 222 
Electronics Design, Cambridge, UK).   223 
Electromyography  224 
Electromyography (EMG) electrodes (Ag–AgCl, 8-mm diameter; 20 mm intra-electrode 225 
distance) were placed on three agonist muscles (rectus femoris, vastus lateralis and vastus 226 
medialis) in a bipolar arrangement according to recommendations (21) with reference electrodes 227 
placed over the patella of the dominant knee. The EMG signals were amplified (100×) and 228 
filtered between 13 - 1000 Hz (Coulbourn Instruments, Allentown, PA) and digitized at 2,000 229 
Hz. Mechanical recordings from the dynamometer corresponding to torque, velocity and position 230 
were recorded online at 2,000 Hz. All analog signals were digitized using a 1401 A–D converter 231 
and Spike 2 software [Cambridge Electronics Design (CED), Cambridge, UK]. 232 
Transcranial Magnetic Stimulation (TMS) 233 
TMS was delivered via a concave double cone coil (Magstim 200, Magstim, Whitland, 234 
UK, 11.0-cm outside diameter) over the motor cortex area to elicit motor-evoked potentials 235 
(MEPs) and torque during voluntary contractions of the dominant knee extensor muscles as 236 
described before (40). The vertex of the motor cortex was identified, and the scalp was marked 237 
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1.0 cm lateral to the vertex (over the motor area corresponding to the dominant knee extensors) 238 
to ensure repeatability of coil placement during the experimental protocol. The optimal coil 239 
position of the TMS was determined during brief contractions of the knee extensor muscles at 240 
20% MVIC. TMS was elicited during the contractions and fine adjustments in the TMS coil 241 
position (~0.5 cm) were made to determine which site evoked the largest superimposed twitch 242 
(SIT) torque and MEP of the rectus femoris muscle. Optimal stimulator intensity was also 243 
determined with brief contractions (2-3 s) of knee extensor muscles (50% MVIC), which is the 244 
intensity that is known to elicit maximal MEPs (51). The intensity of the stimulation (% maximal 245 
of stimulator intensity) was increased by 5% increments until maximal twitch torque of the 246 
quadriceps and maximal MEP of the rectus femoris muscle were elicited. The brief contractions 247 
at 50% MVIC were separated by 30-s rest periods to avoid fatigue when establishing the 248 
intensity of TMS.  249 
Electrical Stimulation 250 
 Single-pulse (200 µs duration, 400 V) electrical stimulation was used for femoral nerve 251 
and percutaneous muscle stimulation (DS7AH; Digitimer, Ltd., Welwyn Garden City, UK) to 252 
elicit maximal compound muscle action potentials (Mmax) and twitch contractions at rest and 253 
during MVICs of the knee extensor muscles. 254 
Femoral Nerve Stimulation: The femoral nerve innervating the knee extensor muscles was 255 
stimulated supramaximally (120 – 600 mA) with a single pulse to elicit the maximal compound 256 
muscle action potential (Mmax).  The cathode electrode (Ambu Neuroline electrodes, Denmark; 257 
1.5 cm diameter) was placed over the femoral nerve within the femoral triangle and the anode 258 
was placed over the greater trochanter of the femur. The intensity of the nerve stimulation was 259 
determined by increasing the current until the twitch amplitude plateaued. The stimulation 260 
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intensity was then increased further by 20% to ensure a maximal activation of the muscles within 261 
the area of stimulation.  262 
Percutaneous Muscle Stimulation: To assess voluntary muscle activation and twitch properties, 263 
the knee extensor muscles were stimulated with a single pulse (150 – 750 mA) via custom-made 264 
pad electrodes (6 cm × ~15 cm) placed over the quadriceps muscles. The cathode was placed 265 
near (within 10 cm) the area of the femoral triangle and the anode was placed proximal to the 266 
patella without hindering knee flexion/extension of the participant. The stimulator intensity was 267 
determined by increasing the current until the twitch amplitude plateaued, then the stimulation 268 
intensity was increased further by 20% to ensure a maximal activation of the muscles in the area 269 
of stimulation. This stimulation intensity was used for the remainder of the session. The twitch 270 
amplitude elicited via percutaneous and femoral nerve stimulation were linearly correlated (r
2
 = 271 
0.653, P < 0.001). Percutaneous muscle stimulation was used throughout the experimental 272 
protocol for assessment of voluntary activation and twitch properties, because percutaneous 273 
stimulation was more tolerable than nerve stimulation. Using the supramaximal intensity, three 274 
muscle stimulations were applied, each separated by ~15 s to assess electrically-evoked twitch 275 
contractile properties in a non-potentiated state.  276 
Experimental Protocol 277 
The experimental protocol entailed: 278 
(1) Baseline MVICs: Participants completed at least three MVICs for ~4 seconds each with 279 
the knee extensor muscles, positioned in 90° of hip and knee flexion. Participants then performed 280 
four additional MVICs during which TMS and electrical stimulation were superimposed to 281 
estimate voluntary activation (see the ‘data analysis’ section for calculations). Electrically-282 
evoked, potentiated twitch contractions were also elicited at rest immediately after each MVIC to 283 
determine contractile properties and voluntary activation of the knee extensor muscles. Each 284 
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baseline MVIC was separated by 2.5 minutes, to minimize the effect of fatigue prior to 285 
beginning the dynamic fatiguing task. 286 
(2) Baseline Maximal Voluntary Concentric Contractions (MVCCs): Participants warmed-up 287 
with 10 MVCCs with a load equivalent to 20% of MVIC. These isotonic contractions were 288 
performed through an ~85º range of motion, from 90°of knee flexion until 5°of knee flexion. 289 
Participants then rested for 2.5 minutes, before initiating the dynamic fatiguing task.  290 
(3) Dynamic fatiguing task: The fatiguing protocol involved 120 isotonic MVCCs of the 291 
knee extensor muscles through an ~85º range of motion (as above) with 1 MVCC performed 292 
every 3 seconds (6-minute task). Participants actively extended the knee, then the dynamometer 293 
passively returned the leg to the starting position at 90º of knee flexion after each MVCC.  294 
(4) Recovery Contractions: The recovery protocol involved sets of brief contractions 295 
immediately after the fatiguing task, and then at 5 and 20 minutes of recovery.  Each set of 296 
contractions involved an MVIC (with a superimposed TMS and percutaneous muscle 297 
stimulation) followed by an additional electrically-evoked twitch contraction and then five 298 
successive MVCCs.  299 
Participants received strong verbal encouragement throughout the maximal effort 300 
contractions. During all MVCCs, participants were instructed to “kick as hard and as fast as 301 
possible” and each MVCC was initiated via strong verbal command from the authors: “KICK”. 302 
The authors provided the verbal cue each 3-s based on a visual cue from a custom-designed data 303 
collection program, and participants were encouraged to maintain maximal effort throughout the 304 
dynamic fatiguing task using several standard statements of encouragement.  305 
Data Analysis 306 
The torque during the MVICs was quantified as the average value over a 0.1 s interval 307 
prior to the onset of the TMS pulse. The maximum angular velocity, power and resistance torque 308 
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during MVCCs were quantified during the concentric phase of the contraction. The average 309 
resistance torque during MVCCs was calculated as the average torque during the concentric 310 
phase of the knee extension contraction. The duty cycle was calculated as: (active contraction 311 
time) · (active contraction time + relaxation time)
-1
. The variables from the dynamic fatiguing 312 
task are presented as the average from five consecutive contractions, at baseline (contractions 1-313 
5) or the end of the fatiguing task (contractions 116-120). 314 
Voluntary activation was assessed with both TMS and electrical stimulation. Voluntary 315 
activation with TMS was estimated with the SIT expressed as a percentage of the total torque i.e. 316 
[SIT · (MVIC + SIT)
-1
 · 100%] (17).  For electrically evoked contractions, voluntary activation 317 
was calculated using the following equation: voluntary activation = (1 – SIT · Potentiated 318 
Twitch
-1
) × 100% (17, 50). Contractile properties of the knee extensor muscles were quantified 319 
from the potentiated twitch elicited with percutaneous electrical stimulation.  Variables included 320 
the peak amplitude of the potentiated twitch, contraction time, and half relaxation time. Half 321 
relaxation time was determined as the time interval in milliseconds (ms) elapsed from the peak 322 
twitch amplitude until the torque reached 50% of the peak twitch amplitude. Post-activation 323 
potentiation (PAP) from electrically-evoked twitch contractions was calculated as: (potentiated 324 
twitch amplitude - non-potentiated twitch amplitude) · non-potentiated twitch amplitude
-1
 · 325 
100%.  326 
Electrophysiological properties of the knee extensors were also assessed with peak-to-327 
peak amplitude of the MEPs for the agonist muscles (rectus femoris, vastus lateralis and vastus 328 
medialis) elicited via TMS during MVICs. Similar results were observed for the MEP amplitude 329 
and area, thus, only MEP amplitude results are presented. The duration of the silent period was 330 
determined as the interval from the time of the TMS to the return of continuous EMG after the 331 
MEP (47). Reduction in variables (MVIC torque, MVCC velocity, power, duty cycle, range of 332 
motion, peak resistance torque, and average resistance torque, voluntary activation, twitch 333 
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amplitude, contraction time, half relaxation time, peak rate of relaxation, EMG silent period and 334 
MEP (%Mmax)) for before and after the fatiguing task, were calculated as [1 – (end value · 335 
baseline value
-1
)] × 100%. Representative traces of raw data are presented in Figure 1, for 336 
dynamic contractions (Fig. 1A) and MVCs with stimulations (Fig. 1 B-F).  337 
[Figure 1] 338 
Homeostatic model assessment for assessing insulin resistance (HOMA-IR) was 339 
calculated using the fasting plasma insulin concentration (FPI, mU·L
-1
) and fasting plasma 340 
glucose (FPG, mmol·L
-1
): HOMA-IR = (FPI × FPG) · 22.5
-1
. 341 
Statistics 342 
Values are reported as mean ± SD in the text and displayed as mean ± SE in the figures. 343 
Participant characteristics and baseline muscle function (Tables 1 and 2) were compared across 344 
groups using a univariate analysis of variance (ANOVA) with two between subject factors 345 
(group: T2D vs controls, and sex: male vs. female). 346 
To determine changes over time during the dynamic fatiguing contraction or during the 347 
20-minute recovery period (task end, 5 mins and 20 mins post the dynamic contraction), mixed 348 
model analysis of variance with group and sex as between subject factors and repeated measures 349 
over time was used for the various dependent variables (MVIC torque, MVCC velocity, power, 350 
duty cycle, range of motion, peak applied torque, and average applied torque, voluntary 351 
activation, twitch amplitude, contraction time, half relaxation time, peak rate of relaxation, EMG 352 
silent period and MEP (%Mmax)). For each ANOVA, the sphericity of data was determined, and 353 
technical corrections were performed when necessary. If needed, post hoc analysis with 354 
Bonferroni corrections were applied when an F test was significant. Pearson correlation 355 
coefficients (r) were used to determine associations between variables including fatigability 356 
(reductions in MVIC and MVCC), participant characteristics (fasting plasma glucose, HbA1c, 357 
estimated VO2 peak, skeletal muscle mass, daily step count, and questionnaire scores), baseline 358 
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muscle characteristics (MVIC strength, MVCC power, voluntary activation, and potentiated 359 
twitch amplitude), and measurements of fatigue-related changes in the potentiated twitch and 360 
voluntary activation. Linearity of bivariate correlations was verified with visual inspection, to 361 
confirm there were no violations of the assumptions of normality, linearity, and 362 
homoscedasticity.  363 
Significance was determined at P < 0.05 and all analyses were performed using IBM 364 
Statistical Package for Social Sciences (SPSS, V24). 365 
RESULTS 366 
Baseline Measurements 367 
 Participant and baseline characteristics are presented in Table 1. The T2D and control 368 
groups were similar in age (group effect, P = 0.985), BMI (group effect, P = 0.172), and daily 369 
physical activity (step count; group effect, P = 0.895). The control and T2D groups had similar 370 
body fat (group effect, P = 0.310), estimated VO2 peak (group effect, P = 0.231) and skeletal 371 
muscle mass in the dominant leg (group effect, P = 0.724).  372 
As expected, people with T2D had higher HbA1c (group effect, P < 0.001), fasting plasma 373 
glucose (group effect, P < 0.001), fasting plasma insulin (group effect, P = 0.001) and HOMA-374 
IR (group effect, P < 0.001) compared with controls (Table 1). People with T2D and controls 375 
had similar plasma thyroid-stimulating hormone concentrations (1.86 ± 0.89 vs. 1.58 ± 0.89 376 
mU·L
-1
, respectively; group effect, P = 0.306). People with T2D and controls demonstrated no 377 
signs of anemia, hemoglobin (14.2 ± 1.8 vs. 14.6 ± 1.7 g·dL
-1
, respectively; group effect, P = 378 
0.428) and hematocrit (42.4 ± 3.3 vs. 42.3 ± 4.0%, respectively; group effect, P = 0.974) 379 
concentrations were similar between the groups. Among the people with T2D, 14 people were 380 
prescribed metformin and 11 people were prescribed a statin medication. Among controls, 0 381 
people were prescribed metformin and 4 people were prescribed a statin medication. Although 382 
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not a primary aim of the study, it is noteworthy that people with T2D prescribed to a statin 383 
medication had similar reductions in MVCC power (time × statin effect, P = 0.458; statin effect, 384 
P = 0.729) and MVIC torque (time × statin effect, P = 0.742; statin effect, P = 0.571) compared 385 
to people with T2D not prescribed to a statin medication. See Table 1. 386 
[Table 1] 387 
People with T2D and controls had similar knee extensor MVIC torque (group effect, P = 388 
0.421), peak angular velocities (group effect, P = 0.949), peak knee extensor power (group 389 
effect, P = 0.627), electrically-evoked potentiated twitch amplitudes (group effect, P = 0.667), 390 
and post-activation potentiation (group effect, P = 0.368). See Table 2.  Baseline levels of 391 
voluntary activation during MVICs were similar between controls and people with T2D, 392 
quantified with TMS (group effect, P = 0.232) and with electrical stimulation (group effect, P = 393 
0.715; Table 2).  394 
[Table 2] 395 
 For both groups, men and women were similar in age (58.9 ± 9.8 vs. 60.5 ± 8.7 years, 396 
respectively; sex effect, P = 0.646; group × sex, P = 0.617), BMI (28.9 ± 5.3 vs. 27.2 ± 6.2 kg·m
-
397 
2
, sex effect, p = 0.447; group × sex, P = 0.205),  daily physical activity (step count: 8,690 ± 398 
3,220 vs. 7,830 ± 3,400 steps·day
-1
, respectively; sex effect, P = 0.499; group × sex, P = 0.608), 399 
HbA1c (6.10 ± 1.11 vs. 6.19 ± 1.15%, respectively; sex effect, P = 0.612; group × sex, P = 400 
0.568), fasting plasma glucose (106.5 ± 25.7 vs. 102.9 ± 35.2 mg·dL
-1
, respectively; sex effect, P 401 
= 0.614; group × sex, P = 0.786), fasting plasma insulin (46.1 ± 21.2 vs. 45.4 ± 29.0 pMol, 402 
respectively; sex effect, P = 0.891; group × sex, P = 0.118), HOMA-IR (2.06 ± 1.14 vs. 2.17 ± 403 
2.01 AU, respectively; sex effect, P = 0.762; group × sex, P = 0.191) and thyroid-stimulating 404 
hormone (1.75 ± 1.03 vs. 1.64 ± 0.68 mU·L
-1
, respectively; sex effect, P = 0.753; group × sex, P 405 
= 0.520).  406 
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Men however, had less body fat than women (28.0 ± 6.6 vs. 38.3 ± 9.6%, respectively; 407 
sex effect, P < 0.001, group × sex, P = 0.142) and greater skeletal muscle mass of the leg (9.81 ± 408 
1.37 vs. 6.54 ± 1.24 kg, respectively; sex effect, P < 0.001; group × sex, P = 0.116). For both 409 
groups men also had a larger MVIC torque (204.6 ± 63.1 vs. 116.9 ± 34.7 Nm, respectively; sex 410 
effect, P < 0.001, group × sex, P = 0.905), similar MVCC peak angular velocity (342.3 ± 56.6 411 
vs. 318.3 ± 41.2 deg·s
-1
, respectively; sex effect, P = 0.184; group × sex, P = 0.620), greater 412 
MVCC peak power (329.0 ± 120.4 vs. 213.1 ± 71.1 Watts, respectively; sex effect, P = 0.004, 413 
group × sex, P = 0.453) and a larger electrically-evoked twitch amplitude (50.3 ± 21.0 vs. 31.7 ± 414 
4.8 Nm, respectively; sex effect, P = 0.004, group × sex, P = 0.670).  Baseline voluntary 415 
activation measured during the MVICs (92.6 ± 5.2 vs. 93.6 ± 2.7%, respectively; sex effect, P = 416 
0.529, group × sex, P = 0.955) and post-activation potentiation (60.0 ± 26.7 vs. 84.6 ± 69.9%, 417 
respectively; sex effect, P = 0.258, group × sex, P = 0.185) was similar for men and women.  418 
Men and women did not differ in estimated VO2 peak (31.0 ± 7.2 vs. 26.0 ± 8.6 mL·kg
-
419 
1
·min
-1
, respectively; sex effect, P = 0.060; group × sex, P = 0.063), although there was a trend 420 
toward significance. Closer examination showed that the control men and women had similar 421 
estimated VO2 peak (30.1 ± 7.0 vs. 30.1 ± 9.7 mL·kg
-1
·min
-1
; sex effect, P = 0.99); however, 422 
among people with T2D, men had greater estimated VO2 peak compared to women (32.0 ± 7.7 423 
vs. 22.0 ± 5.1 mL·kg
-1
·min
-1
;
 
sex effect, P = 0.010).  424 
 Perception of Fatigue, Depression, and Sleep Quality: People with T2D had similar 425 
reports of perceptions of daily fatigue on cognitive function (FIS cognitive; group effect, P = 426 
0.216), physical function (FIS physical; group effect, P = 0.302), and psychological function 427 
(FIS psychological; group effect, P = 0.328) compared with controls. See Table 1. 428 
People with T2D and controls reported low but similar scores on the depression scale 429 
(group effect, P = 0.301), with no one reporting a clinically significant level of depression (GDS 430 
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score > 5). Sleep quality was similar in people with T2D and controls (group effect, P = 0.415). 431 
See Table 1. The mean scores were consistent with assessments of ‘healthy control’ sleepers; 432 
however, some individuals reported ‘poor’ sleep quality (PSQI score > 5) (10).  433 
Fatigability and Recovery 434 
 MVCC angular power and velocity: Both the control group and people with T2D had 435 
reductions in MVCC power during the dynamic fatiguing task (time effect, P < 0.001), but this 436 
reduction was greater in people with T2D (time × group, P < 0.001; Figure 2A). Recovery, 437 
however, was similar for both groups (time effect, P < 0.001; group effect, P = 0.291; time × 438 
group, P = 0.548). 439 
People with T2D demonstrated greater reductions in MVCC peak angular velocity 440 
compared with controls during the dynamic fatiguing task (time effect, P < 0.001; group effect, P 441 
= 0.688; time × group, P = 0.03). During recovery, both groups demonstrated increases in 442 
MVCC angular velocity after the dynamic fatiguing task (time effect; P < 0.001), however, 443 
people with T2D had lower MVCC angular velocity than controls throughout the recovery 444 
period (R05 & R20: group effect, P = 0.012) with no interaction (time × group, P = 0.865).  445 
 [Figure 2] 446 
 The reduction of MVCC power during the fatiguing task was not different between men 447 
and women (last 5 contractions: 29.2 ± 20.1% vs. 38.7 ± 16.8% reduction, respectively; time × 448 
sex, P = 0.524) for either group (time × group × sex, P = 0.762; sex effect, P = 0.104). During 449 
recovery (R05 & R20), the increase in MVCC power (time effect, P < 0.001) was similar for 450 
men and women (sex effect, P = 0.634; time × sex, P = 0.473; time × group × sex, P = 0.276).  451 
Men and women demonstrated a similar reduction in MVCC velocity during the fatiguing 452 
task (last 5 contractions: 23.6 ± 18.8% vs. 31.9 ± 21.2% reduction, respectively; time × sex, P = 453 
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0.542; time × group × sex, P = 0.621) and similar recovery after the fatiguing task (time × sex, P 454 
= 0.268; time × group × sex, P = 0.669).  455 
Duty Cycle: The duty cycle (work:rest ratio) was similar between people with T2D and 456 
controls during the first five dynamic contractions (group effect, P = 0.146). The duty cycle 457 
increased during the fatiguing task (due to slower contraction velocity), but this increase was 458 
similar between people with T2D and controls (time effect, P = 0.031; time × group, P = 0.663). 459 
The duty cycle was similar for men and women at the start of the fatiguing task (13.9 ± 1.8% vs. 460 
14.6 ± 1.7%, respectively; sex effect, P = 0.419; group × sex, P = 0.601), and the increase in 461 
duty cycle at the end of the fatiguing task was similar (27.1 ± 19.5% vs. 28.4 ± 21.3% increase, 462 
respectively; time effect, P < 0.001; time × sex, P = 0.903). 463 
Range of Motion:  People with T2D and controls performed the concentric knee 464 
extension through a similar range of motion (baseline: 79.9 ± 9.0 vs. 80.2 ± 10.9 deg; group 465 
effect, P = 0.898) at the start of the fatiguing task, and the range of motion decreased similarly 466 
for both groups at the end of the fatiguing task (last 5 contractions: 74.1 ± 8.6 vs. 78.4 ± 10.8 467 
deg; time effect, P = 0.006; time × group, P = 0.137). Men and women performed the concentric 468 
knee extension through a similar range of motion at the start of the fatiguing task (80.9 ± 8.3 vs. 469 
79.0 ± 11.6 deg; sex effect, P = 0.587) and had similar reductions in range of motion (last 5 470 
contractions: 76.5 ± 7.1 vs. 75.9 ± 12.5 deg; time × sex, P = 0.711; time × group × sex, P = 471 
0.974). 472 
Applied Torque: The peak applied torque during the concentric knee extension was 473 
similar for people with T2D compared with controls at the start of the fatiguing task (66.9 ± 24.8 474 
vs. 62.7 ± 16.5 Nm, respectively; group effect, P = 0.772).  Similarly, the average applied torque 475 
did not differ between the T2D and control groups (47.9 ± 19.0 vs. 43.4 ± 13.3 Nm, respectively; 476 
group effect, P = 0.563). The applied torque decreased during the dynamic fatiguing task more 477 
for people with T2D compared with healthy controls, for both the peak torque (19.5 ± 8.6% vs. 478 
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13.4 ± 10.3% reduction, respectively; time effect, P < 0.001; time × group, P < 0.001) and the 479 
average torque (17.3 ± 11.6% vs. 12.0 ± 8.9% reduction, respectively; time effect, P < 0.001; 480 
time × group, P < 0.001).  481 
Because men were stronger than women, the peak applied torque (75.6 ± 21.6 vs. 62.7 ± 482 
16.5 Nm, respectively; sex effect, P = 0.001) and the average applied torque (53.9 ± 16.9 Nm vs. 483 
35.9 ± 8.7 Nm, respectively; sex effect, P = 0.001) during the concentric phase of the dynamic 484 
knee extension was greater for men at the start of the fatiguing task. Men and women had a 485 
similar reduction in both peak (14.5 ± 11.0% vs. 18.9 ± 7.8% reduction; time effect, P < 0.001; 486 
time × sex, P = 0.136) and average torque (12.9 ± 11.4% vs. 16.8 ± 9.3% reduction; time effect, 487 
P < 0.001; time × sex, P = 0.236) at the end of the fatiguing task. 488 
 MVIC Torque: The reduction in MVIC torque after the dynamic fatiguing contraction 489 
(time effect, P < 0.001) was greater in the T2D group than controls (time × group, P = 0.04; 490 
Figure 2B). MVIC torque increased during the 20 minutes of recovery (time effect, P < 0.001), 491 
and the increase was similar between the T2D and control groups (R05 & R20: group effect, P = 492 
0.120; time × group, P = 0.186).  493 
 Men and women had similar reductions in MVIC torque after the dynamic fatiguing 494 
contraction (End Task: 31.5 ± 20.1% vs. 31.4 ± 9.6% reduction, respectively; time effect, P < 495 
0.001; sex effect, P = 0.917; time × sex, P = 0.995; time × group × sex, P = 0.725). Men and 496 
women also had similar increases in MVIC torque during recovery (R05 & R20: time effect, P < 497 
0.001; sex effect, P = 0.774; time × sex, P = 0.951; time × group × sex, P = 0.110). See Figure 498 
2B.  499 
Contractile Properties for the Electrically-Evoked Potentiated Twitch 500 
 Twitch Amplitude: The electrically-evoked potentiated twitch amplitude was reduced for 501 
all participants during and immediately after the fatiguing contraction (time effect, P < 0.001); 502 
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however, people with T2D had greater reductions than controls (time × group, P = 0.010). 503 
Similarly, the twitch amplitude increased during recovery (time effect, P < 0.001) but people 504 
with T2D recovered more slowly and the twitch was more depressed, even at 20 mins post 505 
exercise, compared with controls (R05 & R20: group effect, P = 0.027). See Figure 3A. 506 
[Figure 3] 507 
Men and women had similar reductions in potentiated twitch amplitude by the end of the 508 
fatiguing task for both the T2D and control groups (40.3 ± 27.6% vs. 39.8 ± 18.0% reduction; 509 
time effect, P < 0.001; sex effect, P = 0.267; time × sex, P = 0.702; time × group × sex, P = 510 
0.337).  During recovery, men and women demonstrated similar relative increases in potentiated 511 
twitch amplitude (R05 & R20: time effect, P < 0.001; sex effect, P = 0.233; time × sex, P = 512 
0.555; time × group × sex, P = 0.487).  513 
 Half Relaxation Time: People with T2D and controls, both men and women, had similar 514 
increases in half relaxation time of the potentiated twitch after the fatiguing contraction (time 515 
effect, P = 0.001; sex effect, P = 0.568; time × group, P = 0.511; time × sex, P = 0.368; time × 516 
group × sex, P = 0.982; group effect, P = 0.321). During the 20-minutes of recovery (task end, 517 
and at 5 and 20 minutes post exercise), the half relaxation time decreased in all groups (time 518 
effect, P = 0.002; group effect, P = 0.115; sex effect, P = 0.696; time × group, P = 0.458; time × 519 
sex, P = 0.440; time × group × sex, P = 0.747).  520 
Contraction Time: People with T2D and controls, both men and women, demonstrated no 521 
change in contraction time of the electrically-evoked potentiated twitch during the fatiguing task 522 
(time effect, P = 0.377; group effect, P = 0.792; sex effect, P = 0.110; time × group, P = 0.564; 523 
time × sex, P = 0.212; time × group × sex, P = 0.717), or during the 20-minute recovery (task 524 
end and at 5 and 20 minutes post exercise) (time effect, P = 0.532; group effect, P = 0.717; sex 525 
effect, P = 0.126; time × group, P = 0.732; time × sex, P = 0.158; time × group × sex, P = 526 
0.996). See Table 2.   527 
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[Table 2] 528 
Voluntary Activation 529 
 Voluntary Activation (Electrical Stimulation): Voluntary activation decreased in people 530 
with T2D and controls during the fatiguing contraction (End Task: 84.2 ± 9.3% vs. 86.4 ± 7.3%, 531 
respectively; time effect, P < 0.001), but this decrease did not differ between groups (time × 532 
group, P = 0.840; Figure 3B). Men and women showed similar reductions in voluntary activation 533 
by the end of the fatiguing contraction (87.5 ± 7.6% vs. 81.8 ± 8.1%, respectively; sex effect, P = 534 
0.456; time × sex, P = 0.247; time × group × sex, P = 0.506). Voluntary activation remained 535 
depressed during the recovery period after the fatiguing task for all groups (time effect, P = 536 
0.408; time × group, P = 0.420; time × sex, P = 0.260; time × group × sex, P = 0.348; sex effect, 537 
P = 0.792). 538 
 Superimposed Twitch Amplitude (TMS): The SIT increased (i.e. voluntary activation 539 
decreased) in both people with T2D and controls (time effect, P = 0.015) and this effect was 540 
similar for both groups (time × group, P = 0.995, Table 2) and for men and women across the 541 
groups (sex effect, P = 0.490, time × sex, P = 0.625; time × group × sex, P = 0.717). During the 542 
20-minute recovery, the superimposed twitch amplitude decreased (voluntary activation 543 
increased) (time effect, P = 0.039), similarly for people with T2D and controls (time × group, P 544 
= 0.600, Table 2) and similarly for men and women (sex effect, P = 0.944; time × sex, P = 0.146; 545 
time × group × sex, P = 0.443).  546 
EMG Response to Stimulation: Mmax, MEP, Silent Period 547 
Maximal compound muscle action potential (Mmax): The Mmax did not change during the 548 
fatiguing task for participants with T2D or controls for the rectus femoris (time effect, P = 0.212; 549 
time × group, P = 0.176; group effect, P = 0.392; group × sex, P = 0.805; time × sex, P = 0.357; 550 
time × group × sex, P = 0.741), vastus lateralis (time effect, P = 0.697; time × group, P = 0.688; 551 
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group effect, P = 0.825; group × sex, P = 0.804; time × sex, P = 0.294; time × group × sex, P = 552 
0.989), or vastus medialis (time effect, P = 0.403; time × group, P = 0.449; group effect, P = 553 
0.885; group × sex, P = 0.278; time × sex, P = 0.187; time × group × sex, P = 0.503). See Table 554 
2.   555 
The Mmax did not change during the 20-minute recovery period for participants with T2D 556 
or controls for the rectus femoris (time effect, P = 0.588; time × group, P = 0.628; group effect, 557 
P = 0.880; group × sex, P = 0.906; time × sex, P = 0.623; time × group × sex, P = 0.901), vastus 558 
lateralis (time effect, P = 0.653; time × group, P = 0.763; group effect, P = 0.727; group × sex, P 559 
= 0.803; time × sex, P = 0.830; time × group × sex, P = 0.973), or vastus medialis (time effect, P 560 
= 0620; time × group, P = 0.736; group effect, P = 0.997; group × sex, P = 0.254; time × sex, P 561 
= 0.940 time × group × sex, P = 0.157). See Table 2.   562 
Motor evoked potential (MEP): The MEP amplitude (%Mmax) evoked during the MVC 563 
increased after the fatiguing task for the men and women with T2D and controls for the rectus 564 
femoris (time effect, P = 0.001; time × group, P = 0.876; group effect, P = 0.422; group × sex, P 565 
= 0.910; time × sex, P = 0.955; time × group × sex, P = 0.142) and vastus lateralis (time effect, P 566 
= 0.037; time × group, P = 0.260; group effect, P = 0.949; group × sex, P = 0.252; time × sex, P 567 
= 0.324; time × group × sex, P = 0.231), but not for the vastus medialis (time effect, P = 0.139; 568 
time × group, P = 0.796; group effect, P = 0.777; group × sex, P = 0.747; time × sex, P = 0.144; 569 
time × group × sex, P = 0.728). See Table 2.   570 
The MEP amplitude (%Mmax) reduced during recovery for men and women with T2D and 571 
controls for the rectus femoris (time effect, P < 0.001; time × group, P = 0.156; group effect, P = 572 
0.176; group × sex, P = 0.986; time × sex, P = 0.588; time × group × sex, P = 0.965) and vastus 573 
lateralis (time effect, P = 0.042; time × group, P = 0.521; group effect, P = 0.494; group × sex, P 574 
= 0.266; time × sex, P = 0.153; time × group × sex, P = 0.305), but not for the vastus medialis 575 
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(time effect, P = 0.126; time × group, P = 0.958; group effect, P = 0.726; group × sex, P = 0.859; 576 
time × sex, P = 0.678; time × group × sex, P = 0.952).  577 
Silent Period: The EMG silent period, assessed during the MVIC, increased during the 578 
fatiguing task for the rectus femoris (time effect, P < 0.001; time × group, P = 0.615; group 579 
effect, P = 0.632; group × sex, P = 0.731; time × sex, P = 0.502; time × group × sex, P = 0.133), 580 
vastus lateralis (time effect, P = 0.001; time × group, P = 0.187; group effect, P = 0.393; group × 581 
sex, P = 0.803; time × sex, P = 0.406; time × group × sex, P = 0.245) and vastus medialis (time 582 
effect, P = 0.002; time × group, P = 0.103; group effect, P = 0.189; group × sex, P = 0.516; time 583 
× sex, P = 0.406; time × group × sex, P = 0.278). See Table 2.   584 
The EMG silent period decreased during recovery from the fatiguing task for men and 585 
women with T2D and controls for the rectus femoris (time effect, P < 0.001; time × group, P = 586 
0.800; group effect, P = 0.722; group × sex, P = 0.893; time × sex, P = 0.453; time × group × 587 
sex, P = 0.585), vastus lateralis (time effect, P = 0.002; time × group, P = 0.391; group effect, P 588 
= 0.447; group × sex, P = 0.660; time × sex, P = 0.275; time × group × sex, P = 0.368), and 589 
vastus medialis (time effect, P = 0.042; time × group, P = 0.249; group effect, P = 0.799; group 590 
× sex, P = 0.922; time × sex, P = 0.644; time × group × sex, P = 0.409). 591 
Associations 592 
The following variables were associated with reductions in MVIC performed after the 593 
fatiguing task: the relative reduction in potentiated twitch amplitude (r
2
 = 0.364, P = 0.002; 594 
Figure 4A), baseline MVIC torque (r
2
 = 0.140, P = 0.032), HbA1c (r
2
 = 0.145, P = 0.029), fasting 595 
glucose (r
2
 = 0.130, P = 0.042), and HOMA-IR (r
2
 = 0.126, P = 0.046).  596 
The following variables were associated with reductions in MVCC power at the end of 597 
the fatiguing task: estimated VO2peak (r
2
 = 0.494, P <0.001; Figure 4B), reduction in potentiated 598 
twitch amplitude (r
2
 = 0.345, P = 0.002), HOMA-IR (r
2
 = 0.130, P = 0.042), and HbA1c (r
2
 = 599 
0.154, P = 0.024).  600 
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 [Figure 4] 601 
DISCUSSION 602 
 The novel findings of this study were that people with T2D were more fatigable for a 603 
high-velocity dynamic fatiguing task with the knee extensor muscles than healthy controls who 604 
were matched for age, BMI and physical activity, with no differences between men and women. 605 
People with T2D demonstrated greater reductions in MVCC power, MVIC torque and twitch 606 
amplitude after the dynamic fatiguing contraction compared with the healthy controls, indicating 607 
fatigability and impairments in muscle contractile properties were greater for people with T2D. 608 
Voluntary activation was reduced, and the superimposed twitch amplitude and EMG silent 609 
period increased after the dynamic fatiguing task, demonstrating reduced neural drive and 610 
possibly increased intracortical and spinal inhibition; however, these changes were similar for 611 
people with T2D and controls of both sexes. Thus, both muscular and neural mechanisms 612 
(including supraspinal fatigue) contributed to knee extensor fatigability of men and women after 613 
single limb dynamic exercise, however, contractile mechanisms were responsible for the greater 614 
fatigability of people with T2D compared with controls. Accordingly, the primary measures of 615 
fatigability, both the reduction in MVCC power and in the MVIC torque, were correlated with 616 
the reduction in potentiated twitch amplitude. Estimated maximal oxygen consumption (VO2) at 617 
baseline and metabolic factors (HbA1c, fasting plasma glucose and insulin) were also associated 618 
with reduction in MVCC power during the dynamic fatiguing task.    619 
 A strength of this study was that we designed it to understand the effects of T2D on 620 
fatigability of lower limb muscles, while controlling for confounding effects of age, diabetic 621 
polyneuropathy, daily physical activity levels, and participant anthropometrics, by excluding any 622 
patients with clinical signs of diabetic polyneuropathy and by matching groups based on age, 623 
physical activity, estimated aerobic fitness, and BMI. Additionally, people with T2D reported 624 
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similar daily levels of perceived fatigability, sleep quality and depression as the controls, 625 
indicating there was minimal influence of perceptions of fatigue that is often associated with 626 
advanced diabetes (15) and that may confound exercise-induced fatigue of the lower limb. These 627 
findings however may underestimate the group-related differences in fatigability and the 628 
contributing mechanisms may have been different if people with T2D who have diabetic 629 
polyneuropathy were included in the study. For example, after a 20-repetition, moderate-velocity 630 
(120 deg·s
-1
) isokinetic fatiguing task with the knee extensors (28), there was a progressive, 631 
albeit not significant, increase in fatigability in people with T2D and diabetic polyneuropathy (37 632 
± 13% reduction of muscle work) compared with people with T2D and no signs of 633 
polyneuropathy (34 ± 13%) and healthy controls (30 ± 8%). Additionally, people with T2D and 634 
diabetic polyneuropathy demonstrated reduced motor unit number estimates, mean motor unit 635 
firing rates, and impaired neuromuscular propagation in upper and lower limb muscles compared 636 
to controls (4), which indicates impairments along the motor pathway from corticospinal centers 637 
to the interface of the nerve and muscle. These data provide a rationale for an increased role of 638 
central mechanisms contributing to fatigability of limb muscles in people with T2D and 639 
polyneuropathy, although this has not been examined. 640 
Greater Fatigability in People with T2D 641 
The greater fatigability of the knee extensors in people with T2D than controls was 642 
evidenced by markedly greater reductions in MVCC power (42.8% vs. 26.4% reduction) and 643 
MVIC torque at the end of the dynamic tasks (37.6% vs. 26.4% reduction) (Fig. 2).  During the 644 
dynamic fatiguing task, there was a reduction in range of motion and rest time between 645 
contractions (increased duty cycle) but this was similar for both groups. However, the average 646 
applied torque declined more during the fatiguing task for people with T2D than the controls 647 
(17.3% vs. 12.0% reduction), thus, each MVCC required relatively less torque for participants 648 
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with T2D compared to controls at the end of the fatiguing task. Despite this, the participants with 649 
T2D showed larger losses in power than controls. Thus, our study may have underestimated the 650 
magnitude of the difference in loss of power between the groups by up to ~5%. These results are 651 
consistent with previous research demonstrating greater fatigability for isometric contractions of 652 
people with diabetes mellitus (Type 1 or Type 2) of the handgrip (37), dorsiflexor (3), and knee 653 
extensor muscles (6). Importantly, our results clearly indicate that the knee extensor muscles are 654 
more fatigable for dynamic contractions in people with T2D, although these results are not 655 
consistent with that seen for low repetition (20 – 30 repetitions), moderate velocity (120 – 180 656 
deg·s
-1
) isokinetic contractions for this muscle group (18, 28). The greater fatigability of people 657 
with T2D in our study, but not others, could be due to faster contraction velocities or more 658 
repetitions in our protocol. Close examination of the muscle power during the fatiguing task (Fig. 659 
2A) demonstrates that the differences in fatigability between people with T2D and controls did 660 
not become apparent until after ~60 repetitions. Thus, greater fatigability of people with T2D 661 
may only occur with more repetitions or faster contraction velocities, and the magnitude of the 662 
difference in fatigability between people with T2D and controls likely increases as a function of 663 
exercise time.  664 
A unique aspect of our study was that our cohort of T2D participants did not have 665 
advanced stages of the disease, yet lower limb fatigue was greater than in controls matched for 666 
age, BMI and physical activity.  Many of the processes associated with advancing severity of 667 
T2D will exacerbate fatigability of the lower limb even further, including diabetic 668 
polyneuropathy (2) and loss of muscle mass (5), impaired microcirculation (37) and 669 
cardiovascular disease.  We showed however, that even prior to detectable clinical signs of 670 
polyneuropathy and loss of muscle mass, people with T2D display greater fatigability of the knee 671 
extensor muscles that are important for daily function, and as discussed below, was due to 672 
contractile mechanisms. 673 
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Neural Mechanisms of Fatigability 674 
After the fatiguing task, there was a reduction in voluntary activation (assessed via 675 
electrical stimulation) (Fig. 3B), an increase in superimposed twitch amplitude (assessed via 676 
TMS), an increase in EMG silent period and a modest increase in MEP amplitude, each of which 677 
were similar between the people with T2D and control (Table 2). The reduction in voluntary 678 
activation elicited with electrical stimulation after the fatiguing task demonstrated a suboptimal 679 
output from the motor pathway, between activation of the motor cortex and excitation of the α-680 
motor neuron (17).  Because there was an increase in superimposed twitch amplitude elicited 681 
with TMS during the MVIC, the reduced neural drive was in part due to a failure to generate 682 
output from the motor cortex (51). However, this failure was similar across all groups, and thus 683 
did not explain the difference in fatigability in the people with T2D (either the increased 684 
reduction in the MVIC or power).   685 
The increase in silent period reflects intracortical inhibition evoked by the TMS during 686 
the maximal volitional effort which temporarily halts voluntary descending drive (49) and recent 687 
data suggests the silent period may also reflect spinal inhibitory circuitry up to at least 150 ms 688 
after the stimulation (52). Thus, among our participants, there was an increase in intracortical 689 
inhibition, which involves the γ-aminobutyric acid (GABAB) receptors (47), and possibly greater 690 
spinal inhibition (52), but this increase in inhibition was similar across the groups. Although 691 
there was a reduction in voluntary activation, there was a modest increase in the MEP amplitude 692 
elicited by TMS observed in the rectus femoris and vastus lateralis muscles, indicating a net 693 
increase in corticomotor excitability (48), in part due to an increase in cortical excitability, 694 
increased spinal excitability or reduced corticospinal inhibition (29). An increase in MEP 695 
amplitude is often observed with fatiguing exercise (e.g. (26)) and may reflect increased 696 
descending drive despite a failure to increase the motor output. Despite the concomitant 697 
increases in excitability and inhibition of the motor pathway during the fatiguing task, these 698 
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neural adjustments did not directly explain the greater fatigability in the men and women with 699 
T2D compared with controls.  700 
Contractile Mechanisms Primarily Explain Fatigability in People with T2D 701 
The reduction in MVCC power and MVIC torque were associated with the decline of the 702 
electrically-evoked potentiated twitch amplitude, indicating muscle contractile mechanisms 703 
largely explain (~35%) the greater fatigability of people with T2D.  In both groups, a reduction 704 
in twitch amplitude reflected fatigue in the muscle that may be due to disturbances in excitation-705 
contraction coupling, accumulation of metabolites, and/or impaired calcium handling (11, 14), 706 
that ultimately reduce the torque that is able to be produced by the muscle fibers. Volitional and 707 
electrically-evoked contractile function, and lean mass of the knee extensor muscles was not 708 
different between the groups (T2D, control) at baseline, thus, baseline skeletal muscle 709 
morphology and function likely did not contribute to greater fatigability in people with T2D. 710 
However, there is evidence of contractile slowing and reduced muscle strength in people with 711 
diabetes who have polyneuropathy (5).  712 
There are several factors thought to affect the exercising muscle specifically in people 713 
with diabetes which may contribute to the larger fatigue-related reductions in the twitch 714 
amplitude, including: i) impaired neuromuscular transmission (3), ii) impaired calcium kinetics 715 
and cross-bridge detachment, iii) impaired phosphorylation of myosin regulatory light chains (5), 716 
and iv) motor unit loss (1, 4). Among this cohort of people with T2D who had no signs of 717 
diabetic polyneuropathy, there was no reduction in Mmax amplitude, providing evidence of 718 
preserved integrity of the sarcolemma and neuromuscular junction propagation properties in our 719 
cohort of men and women with T2D.  There are relatively few examples of decreased Mmax 720 
amplitude after a fatiguing contraction; however, reduced Mmax has been observed during 721 
sustained isometric contractions of healthy young adults (first dorsal interosseous) (16) and in 722 
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people with type 1 diabetes and diabetic polyneuropathy (ankle dorsiflexors) (3).  Additionally, 723 
there was a similar increase in half-relaxation time between groups in our study, indicating 724 
similar slowing of calcium reuptake into the sarcoplasmic reticulum and slowing of cross-bridge 725 
detachment in the skeletal muscle fibers.  In addition, our data indicates that post-activation 726 
potentiation, assessed by comparing electrically-evoked twitches during a non-potentiated (no 727 
muscular effort within 30 s of the stimulation) and a potentiated state (MVIC performed within 728 
2-s prior to evoked twitch), was similar between groups. Thus, there was probably similar 729 
phosphorylation of myosin regulatory light chains (7) between people with T2D and controls at 730 
baseline. Motor unit loss at baseline or impairments of active motor units in people with T2D 731 
may also underlie the greater impairments in contractile properties compared with controls. 732 
However, the people with T2D had no clinical signs of diabetic polyneuropathy and similar 733 
characteristics (age, strength, muscle mass and contractile properties) compared with controls, 734 
indicating no strong rationale for differences in motor unit numbers between the groups.  735 
 The greater reduction in knee extensor power across both groups, was associated with 736 
estimated fitness level, the gold standard indicator of glycemic control over the preceding two-737 
to-three months (HbA1c) and a proxy of insulin resistance (HOMA-IR).  Although the T2D and 738 
controls groups were matched for fitness, participants with lower estimated fitness had greater 739 
fatigability during the dynamic fatiguing task, indicating that a lower capacity of the 740 
cardiovascular system (systemic blood flow and skeletal muscle oxygen delivery) may contribute 741 
to greater fatigability across both groups. The association of fatigability with HbA1c and the 742 
HOMA-IR indicate that fatigability was greater in people with poorer glycemic control and 743 
greater insulin resistance. The greater insulin resistance (particularly in those with advanced 744 
T2D), may be associated with greater vascular constriction due to increased expression of 745 
endothelin-1 and reduced nitric oxide phosphorylation (38), resulting in reduced skeletal muscle 746 
blood flow during exercise and more perturbed metabolic milieu during exercise in people with 747 
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T2D compared to controls. For example, there is evidence of impaired potassium handling and 748 
calcium regulation (20), and increased lactate concentrations (19, 33) in people with T1D and 749 
T2D after exercise compared with controls. It is therefore probable that people with T2D and 750 
diabetic polyneuropathy or other complications of advanced T2D may have even more severe 751 
fatigability of lower limb muscles than evidenced among our cohort, and these associations 752 
warrant further investigation.  753 
No Sex Differences in Fatigability with T2D  754 
A unique finding of this study was there were no sex-related differences in fatigability of 755 
the knee extensor muscles in a middle-to-older aged cohort of healthy controls or people with 756 
T2D for a fast velocity dynamic fatiguing task. Typically, there are sex differences in fatigability 757 
for isometric and slow-to-moderate velocity fatiguing tasks, particularly in the upper limb in 758 
young healthy and older adults (24, 25). However, the magnitude of the sex differences in 759 
fatigability of young and old adults was diminished for fast-velocity fatiguing contraction tasks 760 
with both the elbow flexor and knee extensor muscles (42), and we found this to be the case in 761 
the middle-to-older aged adults in this study.  We also observed no sex difference in the 762 
reduction in the MVIC measured immediately after the dynamic tasks and during recovery.  763 
However, in several other studies, men showed greater reductions than women in the MVIC 764 
immediately after the dynamic fatiguing contraction (40-42). The mechanism for the sex 765 
difference in the slower recovery of the men than the women in that study was due to contractile 766 
mechanisms with no sex difference in reductions in voluntary activation (40). The sex difference 767 
in fatigability can diminish for older adults for both isometric tasks and dynamic tasks (24, 25, 768 
45). The lack of sex difference in fatigability between our current cohorts could be due to the age 769 
of our participants, whose average age was 60 years, which is older compared to previous reports 770 
demonstrating sex differences (40, 41). The lack of sex differences in fatigability within our 771 
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cohort could be secondary to our a priori participant matching criteria, including similar 772 
estimated maximal aerobic capacity (VO2 peak). Women are expected to have a lower maximal 773 
aerobic capacity than men due to a number of physiological factors including smaller hearts, less 774 
haemoglobin, greater body fat (24, 27); thus, the women in our cohort could be relatively more 775 
fit than the men.  776 
Conclusion 777 
 Men and women with T2D who exhibited no clinical signs of diabetic polyneuropathy, 778 
were more fatigable during and in recovery from a fast-velocity dynamic fatiguing task with the 779 
knee extensors muscles than controls without diabetes who were matched for age, body mass 780 
index, and physical activity. This difference in fatigability occurred when measured as a loss of 781 
power and the reduction of MVIC torque. Furthermore, there was no sex-based differences in 782 
fatigability for the people with T2D and controls. The greater fatigability was associated with 783 
glycemic control and contractile mechanisms, with no observed impairments in neuromuscular 784 
transmission. Although neural mechanisms of fatigability contributed to reductions in knee 785 
extensor power, the lower neural drive was moderate relative to the larger contribution of 786 
contractile mechanisms that explained the greater fatigability of the lower limb in the men and 787 
women with T2D.  788 
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  Units 
Type 2 
Diabetes 
Control 
    (n=17; 10 men) (n = 21, 11 men) 
Age years 59.6 ± 9.0 59.5 ± 9.6 
BMI kg·m-2 29.4 ± 7.0 27.2 ± 4.3 
Body Fat % 36.2 ± 13.8 32.4 ± 7.2 
Duration of Diabetes years 6.83 ± 6.45 0 * 
HbA1c % 7.04 ± 1.11 5.41 ± 0.23 * 
Fasting Plasma Glucose mg·dL
-1
 126.1 ± 32.1 87.1 ± 6.6 *  
Fasting Plasma Insulin pMol 59.1 ± 25.7 35.1 ± 17.5 *  
HOMA-IR AU 3.08 ± 1.71 1.28 ± 0.63 * 
Estimated VO2 Peak mL/kg/min 27.9 ± 8.3 30.1 ± 7.8 
Leg Muscle Mass kg 8.22 ± 1.75 8.52 ± 2.36 
Daily Step Count n 8334 ± 3446 8295 ± 3218 
Questionnaires       
PSQI AU 4.19 ± 2.61 4.90 ± 2.41 
FIS total AU 24.18 ± 29.65 7.19 ± 14.91 
FIS Cognitive AU 6.38 ± 7.43 3.62 ± 4.42 
FIS Physical AU 7.63 ± 8.02 4.62 ± 5.84 
FIS Psychological AU 11.69 ± 15.53 6.67 ± 11.03 
GDS AU 2.00 ± 0 1.95 ± 0.22 
Table 1: Participant characteristics and questionnaire scores. Values are displayed as mean 951 
± SD. BMI, body mass index; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model 952 
assessment of insulin resistance; AU, arbitrary unit; PSQI, Pittsburgh Sleep Quality Index; FIS, 953 
Fatigue Impact Scale; GDS, Geriatric Depression Scale. (* denotes group difference between 954 
controls and T2D, P < 0.05)  955 
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 956 
Table 2: Baseline Muscle Function Before and After the Dynamic Fatiguing Contraction in 957 
People with T2D and Age-and Physical Activity-Matched Healthy Controls without T2D. 958 
Values are displayed as mean ± SD. The relative reduction (%) shown is from baseline to 959 
immediately after the fatiguing tasks (Task End).  People with T2D demonstrated greater 960 
reductions in MVCC power, MVIC torque, and potentiated twitch amplitude compared with 961 
healthy controls. (* denotes group difference between controls and T2D, P < 0.05; † denotes 962 
difference between baseline and task end, P < 0.05).  963 
Abbreviations: MVCC, maximal voluntary concentric contraction; MVIC, maximal voluntary 964 
isometric contraction; VA, voluntary activation; ES, electrical stimulation; SIT, superimposed 965 
twitch; PAP, post-activation potentiation; RF, rectus femoris; VL, vastus lateralis; VM, vastus 966 
medialis; Mmax, maximal compound muscle action potential; NS, not statistically significant.  967 
  968 
    Type 2 Diabetes (n = 17)    Control (n = 21)  
    Baseline Task End Δ (%)   Baseline Task End Δ (%) 
MVCC Power Watts 291 ± 139 163 ± 96 -42.8 ± 24.2†   261 ± 85 199 ± 90 -26.4 ± 15.0†* 
MVCC Velocity deg·s-1 330 ± 62 209 ± 74 -36.2 ± 4.5†   333 ± 37 273 ± 61 -18.9 ± 4.6†* 
Duty Cycle % 13.7 ± 1.2 18.0 ± 2.0 +29.5 ± 20.5†   14.5 ± 2.1 18.1 ± 2.8 +25.8 ± 19.7† 
MVIC Torque Nm 176 ± 80 105 ± 46 -37.6 ± 18.2†   160 ± 59 115 ± 45 -26.4 ± 12.1†* 
Twitch Amplitude Nm 41.1 ± 16.8 21.2 ± 10.1 -44.0 ± 20.4†   43.4 ± 20.1 31.1 ± 12.0 -35.4 ± 20.0†* 
Contraction Time ms 83.1 ± 7.0 80.5 ± 14.0  NS   83.7 ± 10.0 82.4 ± 11.5  NS 
Half-relaxation time ms 70.2 ± 20.7 87.8 ± 30.0 +28.0 ± 12.7†   64.2 ± 18.4 74.1 ± 31.2 +27.4 ± 9.5† 
VA (ES) % 93.4 ± 3.4 84.2 ± 9.3 -12.1 ± 2.6†   92.8 ± 5.0 86.4 ± 7.3 -12.4 ± 4.4† 
SIT % MVIC 2.71 ± 1.72 4.76 ± 2.79 +55.8 ± 41.1†   3.19 ± 1.72 5.04 ± 5.73 +47.7 ± 47.2† 
PAP % 63.2 ± 51.8       74.1 ± 47.3     
Mmax Amplitude                 
RF mV 4.88 ± 1.35 5.13 ± 1.32  NS   4.67 ± 0.78 4.47 ± 0.63  NS  
VL mV 6.40 ± 2.40 5.59 ± 1.27  NS   5.88 ± 2.30 5.70 ± 2.18 NS 
VM mV 7.16 ± 3.40 7.52 ± 3.86  NS   6.82 ± 2.20 6.77 ± 1.20  NS  
MEP Amplitude                 
RF %Mmax 39.5 ± 24.0 54.0 ± 33.2 +50.0 ± 71.0†   49.3 ± 38.6 70.9 ± 44.5 +36.5 ± 59.6† 
VL %Mmax 38.2 ± 24.1 42.8 ± 24.7 +11.3 ± 34.3†   29.0 ± 12.6 40.9 ± 24.5 +27.5 ± 37.1† 
VM %Mmax 47.1 ± 28.9 53.6 ± 37.1  NS   47.7 ± 29.8 52.2 ± 37.4  NS 
EMG Silent Period                 
RF ms 149 ± 116 233 ± 167 +59.5 ± 71.2†   134 ± 41 203 ± 96 +61.0 ± 91.4† 
VL ms 150 ± 112 252 ± 169 +70.5 ± 74.7†   138 ± 58 189 ± 94 +47.3 ± 77.0† 
VM ms 151 ± 112 249 ± 169 +66.5 ± 62.3†   134 ± 36 166 ± 94 +47.1 ± 67.3† 
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FIGURE LEGENDS 969 
Figure 1: Representative data for maximal voluntary concentric contraction (MVCC) 970 
power, range of motion and applied torque, maximal voluntary isometric contraction 971 
(MVIC) torque, superimposed twitch (SIT) torque, potentiated twitch, motor evoked 972 
potential (MEP) and EMG silent period. A. Calculated power (applied torque × half-wave 973 
rectified velocity), range of motion and applied torque signals of a 62-year old control woman 974 
performing five MVCCs at the start (black lines) and end (grey lines) of the fatiguing task. The 975 
torque (B) and EMG (C) signal of the woman performing an MVIC with TMS-elicited SIT 976 
during the MVIC and electrical stimulation evoked twitches during the MVIC and at rest. The 977 
TMS-elicited SIT (D), electrically-evoked potentiated twitch (E) torque, and vastus lateralis 978 
EMG (F) signal displaying the MEP and EMG silent period from before (black line) and after 979 
the fatiguing task (grey line).  980 
Figure 2: Fatigability of the maximal voluntary concentric contraction (MVCC) power (% 981 
baseline) (A) and maximal voluntary isometric contraction (MVIC) torque (% baseline) (B) 982 
in response to a dynamic fatiguing task. Values are displayed as mean ± SEM. A. The T2D 983 
group had greater reductions in the mean MVCC power (% baseline power of the mean of first 5 984 
contractions) than controls by the last five contractions of the dynamic fatiguing task. Recovery 985 
of power during the MVCCs at 5 min (R05) and 20 mins (R20) was less for the T2D than control 986 
group.  B.  MVIC torque (% baseline) declined more for the T2D than the control group by the 987 
end of the dynamic fatiguing task (Task End).  Recovery of MVIC was similar between people 988 
with T2D and controls for MVIC torque up to 20 mins after the fatiguing task (R20). (* group 989 
differences at P < 0.05). 990 
 991 
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Figure 3: Electrically-evoked potentiated twitch amplitude (A) and voluntary activation (B) 992 
during and after the dynamic fatiguing task.  Values are displayed as mean ± SEM. A. The 993 
electrically-evoked potentiated twitch amplitude (% baseline) was reduced more for the T2D 994 
group than controls and remained depressed during the 20 mins recovery (P < 0.05). B. 995 
Voluntary activation (assessed with electrical stimulation) declined in both people with T2D and 996 
controls (P < 0.05) but did not differ between groups (P > 0.05). 997 
Figure 4: Associations with fatigability. A.  The reduction in MVIC torque (%) was associated 998 
with the reduction in potentiated twitch amplitude (%) (A; r = 0.603, r
2 
= 0.364, P = 0.002). B. 999 
The reduction in MVCC power (%) was associated with estimated peak aerobic capacity (eVO2) 1000 
(B; r = -0.703, r
2 
= 0.494, P < 0.001).  1001 
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